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Hyperplasia of mammary glands is a common disease 
of the breast in women. The following is a clinical 
report on treatment of the disease by combination of 
acupuncture with medication in 46 cases from 
February 2007 to October 2008. 
CLINICAL MATERIALS  
Diagnostic Criteria 
The Criteria for Diagnosing and Treating Hyperplasia 
of Mammary Glands: 1) vague pain or distending 
pain of the breast mostly on both sides or sometimes 
on one side.1 The pain may be aggravated before 
menstruation or when the emotion fluctuates. 2) 
Breast masses on both sides or on one side vary in 
size, soft and tenacious or hard and tenacious with 
unclear border, and with tenderness but no adhesion. 
3) Ultrasonic examination may show expanded ducts 
and thickened mammary glands. Roentgenogram of 
molybdenum target may show even and denser 
shadow of the mammary glands. 
Exclusive Criteria 
1) Pregnancy and lactation period with severe 
disorder of menstrual cycle; 2) inflammation and 
tumor of the mammary glands; 3) severe primary 
diseases of the heart, liver, kidney and blood system, 
and mental disorder; 4) women who take con- 
traceptives and sexual hormones. 
General Data 
In this series, 90 patients were randomly divided into 
a treatment group and a control group. In the 
treatment group, there were 46 patients, aged 18–56, 
34.0±2.5 on the average, with the illness course from 
3 months to 10 years, 3.5±1.2 years on the average. 
The condition was 17 mild in 17 cases, moderate in 
19 cases, and severe in 10 cases. In the control group, 
there were 44 patients, aged 21–58, 35.0±4.1 on the 
average, with the illness course from 4 months to 11 
years, 4.1±1.3 years on the average. The condition 
was mild in 19 cases, moderate in 17 cases, and 
severe in 8 cases. There were no obvious differences 
in age, illness course and disease condition between 
the two groups (P>0.05).   
METHODS 
For the Treatment Group 
Acupuncture was performed at the main points of 
Wuyi (ST 15), Rugen (ST 18), Hegu (LI 4), Jianjing 
(GB 21), Tianzong (SL 11) and Ganshu (BL 18).  
Taichong (LR 3) was added for exuberant liver-fire.  
Hegu (LI 4) was removed with Taixi (KI 3) and 
Shenshu (BL 23) added for yin-deficiency of the liver 
and kidney. Zusanli (ST 36) and Pishu (BL 20) were 
added for deficiency of both qi and blood.  
Sanyinjiao (SP 6) was added for irregular men- 
struation. Hegu (LI 4) was removed with Waiguan 
(TE 5) added for pain in the shoulders and back.  
The needles were inserted obliquely outward at 150 
degrees for 40 mm into Wuyi (ST 15) and Rugen (ST 
18). The needle was inserted obliquely outward for 
40 mm into Tianzong (SL 11). The needle was 
vertically inserted for 40 mm into Jianjing (GB 21).  
Conventional acupuncture was given at the other 
points. The treatment started on the 10th day of each 
menstruation and was performed once a day for 15 
sessions as one therapeutic course. The curative 
effects were evaluated after 3 menstrual cycles.  
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Medication was given with a prescription consisting 
of Chai Hu (柴胡 Radix Bupleuri) 12g, Yu Jin (郁金
Radix Curcumae) 10g, Yan Hu Suo (延胡索 Rhizoma 
Corydalis) 10g, Wang Bu Liu Xing (王不留行 Semen 
Vaccariae) 10g, Chuan Lian Zi (川楝子 Fructus 
Meliae Toosendan) 10g, Zao Jiao Ci (皂角刺 Spina 
Gleditsiae) 10g, Tu Bie Chong (土鳖虫 Eupolyphaga 
seu Steleophaga) 10g, Dan Shen (丹参 Radix Salviae 
Miltiorrhizae) 15g, and Mu Li (牡蛎 Concha Ostreae) 
15g. Xia Ku Cao (夏枯草 Spika Prunellae) 10g was 
added for patients with exuberant liver-fire. Shan Zhu 
Yu (山茱萸 Fructus Corni) 15g and Shu Di Huang 
(熟地黄 Radix Rehmanniae Praeparata) 20g were 
added for those with yin-deficiency of the liver and 
kidney. Sheng Huang Qi (生黄芪 Radix Astragali seu 
Hedysari) 30g and Dang Gui (当归 Radix Angelicae 
Sinensis) 6g were added for those with deficiency of 
both qi and blood. Zi He Che (紫河车 Placenta 
Hominis) 10g and Nü Zhen Zi (女贞子 Fructus 
Ligustri Lucidi) 10g were added for those with 
irregular menstruation. One dose of the decoction 
was equally divided into two potions to be taken 
twice a day. The medication should be suspended 
during menstruation.   
For the Control Group 
Tamoxifen Citrate Tablets (produced by Jiangsu 
Yangzi River Pharmaceutical Group Co. Ltd.) was 
orally taken 5 days after each menstruation, 10 mg a 
time, twice a day, for 2 weeks. The curative effects 
were evaluated after 3 menstrual cycles. 
Observation of the Curative Effects 
1. Scoring Criteria 
According to the scoring criteria described in Xiandai 
Zhongyi BingXue (现代中医病学) Modern TCM 
Mastosis: 1) In terms of breast masses, the score was 
0 for disappearance of the breast masses after 
treatment, 1 for thickened masses, 2 for the masses 
tenacious as the nose tip, and 3 for the masses hard as 
the forehead. In terms of tenderness of the masses, 
the score was 0 for no tenderness, and 2 for having 
tenderness. In terms of size of the masses (calculated 
according to the long diameter of the largest mass), 
the score was 0 for disappearance of the masses after 
treatment, 1 for the mass ≤2 cm, 2 for the mass >2 
cm but ≤5 cm, 3 for the mass >5 cm. In terms of 
scope of the masses, the score was 0 for dis- 
appearance of the masses after treatment, 1 for the 
masses limited in one or two quadrants of the breasts, 
2 for the masses found in 3–4 quadrants, 3 for the 
masses found in 5–6 quadrants, 4 for the masses 
found in 7–8 quadrants. 2) Breast pain was calculated 
by using a 10-point scale. 3) The score was 0 for no 
mental depression and no irritability, and 1 for having 
mental depression and irritability. 4) The score was 0 
for no anorexia with no fullness sensation in the 
stomach, and 1 for having anorexia with fullness 
sensation in the stomach. 5) The score was 0 for no 
hypochondriac pain, and 1 for having hypochondriac 
pain. 6) The score was 0 for basically normal 
menstruation, and 1 for scanty and dark menstrual 
flow. 7) The score was 0 for no dysmenorrhea, and 1 
for having dysmenorrhea. 8) The illness condition 
was graded: the score 8–14 for mild, the score 15–21 
for the moderate, and the score ≥22 for the severe. 
2. Criteria for Curative Effect 
Clinically cured: The index of curative effect was 
≥90%. Markedly relieved: the index of curative effect 
was 70%–89%. Improved: the index of curative 
effect was 30%–69%. Failed: the index of curative 
effect was <30%. 
3. Comparison of the Scores between the 2 Groups  
In the treatment group of 46 cases, the score was 
25.12±1.2 before treatment, and 10.29±3.42 after 
treatment. In the control group of 44 cases, the score 
was 24.58±2.4 before treatment, and 18.16±2.86 after 
treatment. Obvious improvement was achieved in 
both the groups (P<0.05). However, the curative 
effect in the treatment group was much better than 
that in the control group (P<0.05). 
4. Comparison of Curative Effects between the Two 
Groups 
In the treatment group of 46 cases, 29 cases were 
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clinically cured, 6 cases markedly relieved, 6 cases 
improved and 5 cases failed, with a total effective 
rate of 89.1%. In the control group of 44 cases, 8 
cases were clinically cured, 4 cases markedly 
relieved, 16 cases improved and 16 cases failed, with 
a total effective rate of 63.6%. The curative effect in 
the treatment group was much better than that in the 
control group (P<0.05). 
5. Comparison of the Estradiol, Prolactin and 
Progesterone Levels before and after Treatment 
The average levels of Estradiol, Prolactin and 
Progesterone after treatment were much lower than 
that before treatment in the treatment group (P<0.05); 
while no obvious decline was found in the control 
groups (P>0.05) 
6. Comparison of Relapse Rate between the Two 
Groups 
In a follow-up for half a year, the relapse rate was 6% 
in the treatment group, and 45% in the control group, 
with an obvious difference between the two groups 
(P<0.01) 
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